Comparison of the COBAS TAQMAN™ HIV-1 HPS with VERSANT HIV-1 RNA 3.0 Assay (bDNA) for plasma RNA quantitation in different HIV-1 subtypes

Gómes, Perpétua; Palma, Ana Carolina; Cabanas, Joaquim; Abecasis, Ana; Carvalho, Ana Patrícia; Ziermann, Rainer; Diogo, I; Gonçalves, Fátima; Lobo, Céu Sousa; Camacho, Ricardo Jorge

doi:10.1016/j.jviromet.2006.03.018

Cited by 16 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This creates a dilemma in the treatment of HIV-2 infected patients as viral loads are an integral part of patient monitoring. The five methods for detecting viral loads all routinely detect HIV-1 viral RNA from most group M subtypes, although small differences may exist in quantification capabilities [ 27 - 32 ]. Assays for HIV-2 are mainly developed for research purposes and none are commercially available [ 15 , 28 , 33 - 35 ].…”

Section: Discussionmentioning

confidence: 99%

HIV-2 diagnosis and quantification in high-risk patients

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

HIV-2 diagnosis and quantification in high-risk patients

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Accordingly, periodic viral load monitoring is recommended for HIV-infected patients receiving antiretroviral therapy. Several commercial tests have been approved for the quantitation of HIV RNA in plasma, including (i) the Cobas TaqMan HIV type 1 (HIV-1) test (Roche Molecular Systems, Basel, Switzerland) (24), (ii) the Nuclisens EasyQ HIV-1 (version 1.1) test (the Nuclisens test; Biomerieux, Durham, NC) (12), (iii) the branched DNA Versant HIV-1 RNA (version 3.0) assay (Siemens, Berkeley, CA) (14), and (iv) the m2000rt RealTime HIV-1 test (the m2000rt test; Abbott, Chicago, IL) (13,30).…”

mentioning

confidence: 99%

Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests

Garrido¹,

Zahonero²,

Corral³

et al. 2009

J Clin Microbiol

View full text Add to dashboard Cite

The plasma human immunodeficiency virus (HIV) RNA load is used in the clinical routine for the monitoring of HIV infection and the patient's response to antiretroviral therapy. Other body fluids or dried blood spots (DBS) can be used, however, to assess the level of viremia. The use of DBS may be especially helpful for the monitoring of HIV-infected patients in resource-poor settings, where access to adequate laboratory facilities is often difficult. However, the correlation between the HIV RNA levels in plasma and those in DBSs has not been well established. Paired plasma and DBS samples obtained from HIV type 1 (HIV-1)-infected patients were tested for HIV RNA copy numbers by using two different commercial assays, the Nuclisens EasyQ HIV-1 (version 1.1) test (the Nuclisens test; Biomerieux) and the m2000rt RealTime HIV test (the m2000rt test; Abbott). Nucleic acid extraction was performed manually by using either the Nuclisens isolation kit (which uses the Boom methodology) or the m2000rt sample preparation kit (an iron particle-based method). A total of 103 paired plasma and DBS samples were tested. Viral load results were obtained for 97 (94.2%) samples with the Nuclisens isolation kit and 81 (78.6%) samples with the m2000rt kit. The overall correlation between the RNA loads in plasma and DBS was good, although better results were obtained by the Nuclisens test (R 2 ‫؍‬ 0.87, P < 0.001) than by the m2000rt test (R 2 ‫؍‬ 0.70, P < 0.001). While the specificities were excellent and similar for both the Nuclisens and the m2000rt tests (97.1% and 100%, respectively), the sensitivity was greater by the Nuclisens test than by the m2000rt test (75.8% and 56.6%, respectively). Overall, the viral loads in DBS tended to be lower than those in plasma, with mean differences of 0.3 log unit (standard deviation, 0.5 log unit) and 0.76 log unit (standard deviation, 0.8 log unit) for the Nuclisens and the m2000rt tests, respectively. The levels of agreement between the measurements in plasma and DBS were assessed by using the Bland-Altman plot for each assay. The Nuclisens test gave results within its defined limits (؊0.65 to 1.26) for 95.9% of the samples, while the m2000rt test gave results within its limits (؊0.83 to 2.33) for 100% of the samples. In summary, the HIV-1 load can accurately be quantified by testing DBS by either the Nuclisens or the m2000rt test, although the Nuclisens test may outperform the m2000rt test when nucleic acids are extracted manually.

show abstract

“…By contrast, the group O viruses were not detected by the Roche Monitor Test, v1.5 and were quantified substantially lower, with approximately 2 log 10 copies/ml in the bDNA assay in comparison with the Abbott real-time assay. The comparison of the Roche Taqman assay with the bDNA assay revealed no significant differences between both assays, even in the genetically diverse populations of HIV-1 group M [37].…”

Section: Available Assays In Detailmentioning

confidence: 92%

Molecular assays for monitoring HIV infection and antiretroviral therapy

Wittek

Stürmer

Doerr

et al. 2007

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Infection with HIV results in lifelong persistence of the virus in the body of infected persons, independent of antiretroviral treatment. Therefore, efficient and meaningful therapy monitoring has been developed since its introduction in the 1980s. Whereas, primarily, the measurement of the CD4 cell count was the most important clinical marker of disease progression, nowadays the estimation of plasma viral load with molecular methods plays a major role as a marker of therapy success. To optimize therapy changes in patients failing on antiretroviral therapy regimen, HIV-1 genotyping has been introduced and is now widely accepted as an additional diagnostic tool. Due to this increase in diagnostic parameters, clinicians and virologists have to cope with many different methods. This review should give a brief overview of the current commercially available assays for detection and quantification of HIV, as well as for HIV-1 genotypic resistance testing. Quantitative reverse transcriptase PCR, real-time PCR, nucleic acid sequence-based amplification and the branched DNA system are described in detail, and the advantages and disadvantages are discussed. In addition, two commercially available HIV-1 genotyping assays are compared. However, a general recommendation to favor one system over the other cannot be given, because the final decision of which system to use should be decided on the individual requirements.

show abstract

Comparison of the COBAS TAQMAN™ HIV-1 HPS with VERSANT HIV-1 RNA 3.0 Assay (bDNA) for plasma RNA quantitation in different HIV-1 subtypes

Cited by 16 publications

References 36 publications

HIV-2 diagnosis and quantification in high-risk patients

HIV-2 diagnosis and quantification in high-risk patients

Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests

Molecular assays for monitoring HIV infection and antiretroviral therapy

Contact Info

Product

Resources

About